Abilify vs Rexulti

How they're similar

Both drugs are partial agonists at the D2 dopamine receptor. Both are partial agonists at the 5HT1A serotonin receptor. Both are antagonists at 5HT2A. That receptor profile is the shared backbone, and it's why both drugs sit in the third-generation antipsychotic category alongside cariprazine. Compared with older antipsychotics like haloperidol, this class tends to cause less prolactin elevation, less weight gain (on average, not always), and less of the movement side effects that made older drugs so hard to live with. That said, none of these effects are absent, and both drugs can still cause real problems.

Both are approved for schizophrenia and both are approved as add-on treatment for major depressive disorder when an antidepressant alone isn't enough. That last use is common in outpatient psychiatry. Both are once-daily oral medications, though aripiprazole also comes in long-acting injectable forms. Both share the antipsychotic boxed warning about increased mortality in older adults with dementia-related psychosis, and both share the antidepressant class warning about suicidal thoughts in people under 25.

Both can cause weight gain, though usually modest. Both can raise metabolic markers like fasting glucose and lipids, though usually less than olanzapine or quetiapine. Both can cause akathisia and both can cause activation or insomnia. And both have compulsive behavior warnings on the label, most famously about gambling but also about eating, spending, and sexual behavior. That risk isn't common but it's real, and it can be a serious quality-of-life issue when it happens.

How they differ

The core receptor profile is similar but not identical. Brexpiprazole is a weaker partial agonist at D2 than aripiprazole, meaning it has less intrinsic activity at the receptor. That's part of why it tends to cause less akathisia and less activation. Brexpiprazole also has more activity at alpha-1B and alpha-2C adrenergic receptors, which contributes to its calmer feel and possibly to its usefulness in agitation. Aripiprazole has more affinity for D3 than brexpiprazole does, though it's not the D3-preferring drug the way cariprazine is.

The approved uses are where the practical differences show up.

Aripiprazole has been on the market since 2002 and carries a much longer list of approvals. It covers schizophrenia, acute mania in bipolar I, MDD adjunct, autism-related irritability in children as young as 6, and Tourette syndrome. It also has multiple long-acting injectable forms, which matter for people who prefer or need an injection rather than a daily pill. Aristada is a monthly to every-two-months option, Abilify Maintena is monthly, and Abilify Asimtufii is a every-two-months form. Brexpiprazole has none of those. It's oral only.

The Alzheimer's agitation approval is the differentiator on the brexpiprazole side. In 2023, brexpiprazole became the first drug FDA-approved specifically for agitation associated with Alzheimer's disease. That's a real clinical gap that had been filled with off-label prescribing for decades, often using drugs that weren't studied for that exact use. The approval doesn't mean brexpiprazole is safe in older adults without care. The mortality warning for antipsychotics in dementia still applies. It means there is finally a drug with trial data for that specific population and indication.

Side effect tendencies

The most talked-about difference is akathisia. Aripiprazole is well known for causing it, sometimes to a degree that makes people stop the drug even when it's working on their target symptoms. The rate in trials is often in the 15 to 20 percent range, and in real life it can feel higher because the discomfort is hard to sit with. Brexpiprazole causes akathisia less often, more in the 5 to 10 percent range. That difference is one of the main reasons brexpiprazole exists as a separate drug, and it's the most common reason a prescriber would pick it over aripiprazole for someone with a bad akathisia history.

Activation is the other split. Aripiprazole can feel stimulating for some people, especially early on. It can cause insomnia, restlessness, jitteriness, or a wired feeling that isn't quite akathisia. Brexpiprazole tends to be calmer. Some people find it slightly sedating, which can be a benefit at bedtime or a drawback during the day. The alpha activity is likely part of that calmer profile.

Weight gain is similar between the two, with brexpiprazole possibly a touch heavier on the scale in some studies. Neither is in the same category as olanzapine or quetiapine, but both can add pounds over months. Metabolic effects on glucose and lipids are modest with both. Prolactin elevation is uncommon with either.

The compulsive behavior warning applies to both. This isn't a common effect, but when it happens it can be dramatic and life-changing. Pathological gambling has the most press. Compulsive eating, shopping, and sexual behavior are also reported. The warning is on both labels because it's a class effect of the partial agonist mechanism. Anyone starting either drug should know to report new impulsive behaviors, and family members can be helpful in noticing what the person may not.

Tardive dyskinesia is a risk with any D2-active drug. The third-generation class has a lower rate than older agents, but not zero. Periodic screening exams are worth doing for anyone on long-term treatment.

What tips the choice

Cost is often the first filter. Aripiprazole is generic and inexpensive. Brexpiprazole is brand-only and expensive, often prohibitive without insurance. For a lot of people, cost alone points to aripiprazole as the first try.

Side effect history is the next filter. If someone tried aripiprazole and had bad akathisia, or bad activation, brexpiprazole is a reasonable next step. Many people who couldn't stay on aripiprazole do fine on brexpiprazole. If someone did well on aripiprazole in the past, there's no strong reason to switch. If someone needs a long-acting injectable, aripiprazole is the only option in this pair. Cariprazine also lacks an LAI.

Diagnosis matters at the edges. For autism-related irritability in a child, aripiprazole has the approval and the pediatric data. For Tourette syndrome, aripiprazole is one of a small handful of approved options. For MDD adjunct, either works and the decision is mostly about tolerability and cost. For agitation in Alzheimer's disease, brexpiprazole now has the approval, though the conversation with the family about mortality risk is still an important part of the decision.

For someone with prominent anxiety or agitation as part of their presentation, the calmer profile of brexpiprazole may fit better. For someone with prominent negative symptoms or low motivation as part of schizophrenia, some clinicians reach for aripiprazole first, though the evidence for one being clearly better in that regard is thin.

Common questions

Is Rexulti just Abilify with less akathisia? Roughly, yes, for most practical purposes. The two drugs share the same receptor family and the same broad clinical use in schizophrenia and MDD adjunct. Rexulti has a weaker partial agonist effect at D2, which is why it tends to cause less akathisia and less activation. It also has a differentiating Alzheimer's agitation indication. But the shared receptor profile means most of the class effects (weight, metabolic, compulsive behavior warnings, TD risk) apply to both.

Which is cheaper? Aripiprazole is much cheaper, often by a large margin. It's been generic for years and is available for a few dollars a month at many pharmacies. Brexpiprazole is brand-only, and without insurance the cash price is often several hundred dollars a month or more. Insurance coverage varies, and many plans require a prior authorization for brexpiprazole.

Can I switch from Abilify to Rexulti? Yes, and it's fairly common. The two drugs are similar enough that a direct switch or a short cross-taper is usually well tolerated. The switch is often made because of akathisia or activation on aripiprazole, and many people notice a real improvement in tolerability. The switch should be planned with a prescriber, especially if a long-acting injectable is involved.

Do these cause weight gain? Both can, though usually modest. Neither is in the heavy metabolic category like olanzapine or quetiapine. Weight gain tends to accumulate over months rather than in the first weeks. If weight is a concern, it's worth naming up front so the plan includes monitoring and, if needed, a plan for a switch.

Why is there a gambling warning on both? Because the partial agonist mechanism at dopamine can, in some people, unlock reward-related behaviors that feel out of control. Gambling gets the most attention, but compulsive shopping, eating, and sexual behavior are also on the label. The effect isn't common but it can be severe and rapid when it happens. Anyone starting either drug should know to report any new impulsive urges. Stopping the drug usually resolves the behavior.

Sources

This guide draws on current prescribing information and public health references. It is reviewed for clinical accuracy and updated as guidance changes.

1. U.S. Food and Drug Administration. Aripiprazole (Abilify) prescribing information.
2. U.S. Food and Drug Administration. Brexpiprazole (Rexulti) prescribing information.
3. MedlinePlus, U.S. National Library of Medicine.
4. National Institute of Mental Health. Mental health medications.